BRNS vs NWSA · $38.2M cap vs rev $9.03B
Barinthus Biotherapeutics plc (BRNS) versus NWSA (NWSA) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
NWSA (NWSA) common stock.
Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.
Latest reported NWSA revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 328.1% from 2025-06-30 to 2026-06-30. NWSA currently screens at market cap $0.
BRNS currently screens at market cap $38.2M. NWSA currently screens at market cap $0.
Not investment advice. Open the BRNS and NWSA stock pages for the full models.
Not investment advice.